Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Morel

Showing results (121-130 of 165) with videos related to

Pageof 17
Sort By:
Arthritis Research & Therapy|June 2, 2017
The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identicalDebbie M Boeters, Lukas Mangnus, Sofia Ajeganova, et al.
Annals of the Rheumatic Diseases|February 24, 2018
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's diseaseCem Gabay, Bruno Fautrel, Jürgen Rech, et al.
Annals of the Rheumatic Diseases|June 17, 2016
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registersLouise K Mercer, Johan Askling, Pauline Raaschou, et al.
RMD Open|September 21, 2024
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT studyLars Erik Kristensen, Khai Jing Ng, Marcus Ngantcha, et al.
La Revue De Medecine Interne|July 15, 2023
French national diagnostic and care protocol for Sjögren's diseaseValérie Devauchelle-Pensec, Xavier Mariette, Anas-Alexis Benyoussef, et al.
Journal of the American Academy of Dermatology|March 12, 2016
Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseasesColine Faivre, Axel Patrice Villani, François Aubin, et al.
Rheumatology (Oxford, England)|December 19, 2018
Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease?Céline Anquetil, Eric Hachulla, François Machuron, et al.
Optics Express|October 7, 2021
SI-traceable frequency dissemination at 1572.06  nm in a stabilized fiber network with ring topologyDominik Husmann, Laurent-Guy Bernier, Mathieu Bertrand, et al.
Joint Bone Spine|July 9, 2010
Tocilizumab: therapy and safety managementThao Pham, Pascal Claudepierre, Arnaud Constantin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 25, 2024
Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological DataYann Nguyen, Maxime Beydon, Jacques-Eric Gottenberg, et al.
Pageof 17

Showing results (121-130 of 165) with videos related to

Sort By:
Pageof 17
Arthritis Research & Therapy|June 2, 2017
The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identicalDebbie M Boeters, Lukas Mangnus, Sofia Ajeganova, et al.
Annals of the Rheumatic Diseases|February 24, 2018
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's diseaseCem Gabay, Bruno Fautrel, Jürgen Rech, et al.
Annals of the Rheumatic Diseases|June 17, 2016
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registersLouise K Mercer, Johan Askling, Pauline Raaschou, et al.
RMD Open|September 21, 2024
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT studyLars Erik Kristensen, Khai Jing Ng, Marcus Ngantcha, et al.
La Revue De Medecine Interne|July 15, 2023
French national diagnostic and care protocol for Sjögren's diseaseValérie Devauchelle-Pensec, Xavier Mariette, Anas-Alexis Benyoussef, et al.
Journal of the American Academy of Dermatology|March 12, 2016
Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseasesColine Faivre, Axel Patrice Villani, François Aubin, et al.
Rheumatology (Oxford, England)|December 19, 2018
Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease?Céline Anquetil, Eric Hachulla, François Machuron, et al.
Optics Express|October 7, 2021
SI-traceable frequency dissemination at 1572.06  nm in a stabilized fiber network with ring topologyDominik Husmann, Laurent-Guy Bernier, Mathieu Bertrand, et al.
Joint Bone Spine|July 9, 2010
Tocilizumab: therapy and safety managementThao Pham, Pascal Claudepierre, Arnaud Constantin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 25, 2024
Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological DataYann Nguyen, Maxime Beydon, Jacques-Eric Gottenberg, et al.
Pageof 17